The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
The Hutchmed-originated savolitinib moves towards its first US approval.
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.
The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.